Skip to main content

Security report for biogen.se

Biogen Sweden AB · Healthcare · Sweden

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

78/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Sweden AB operates a professional and comprehensive website focused on biotechnology and healthcare, specifically targeting neurological and rare diseases. The company is positioned as a leading global biotechnology firm with a strong presence in Sweden, offering innovative treatments and scientific advancements. The website is well-structured, professionally designed, and provides detailed information about the company's mission, disease areas, career opportunities, and corporate responsibility. Technically, the site leverages Adobe Experience Manager CMS, modern JavaScript libraries, and integrates cookie consent and analytics tools to ensure compliance and user experience. Security posture is solid with HTTPS enforcement and cookie consent mechanisms, though some security headers and explicit security policies are absent. WHOIS data for the domain www.biogen.se is unavailable, likely due to the domain being a subdomain or managed under a parent domain, but the website content and branding strongly support legitimacy. Overall, the site demonstrates a mature digital presence with good privacy compliance and user trust indicators.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.se

This scan found 19 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
95
Email security
60
DNS health
60
Network security
100
GDPR outside view
83
Average
78

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen Sweden AB is a key player in the biotechnology sector, focusing on neurological and rare diseases. The business model centers on research, development, and commercialization of innovative therapies. The website targets healthcare professionals, patients, and researchers in Sweden, providing localized content and resources. The company maintains a consistent brand image and leverages social media channels for outreach. The absence of direct contact emails or phone numbers on the homepage suggests a controlled communication approach, likely routed through dedicated contact pages. The site’s integration with global Biogen domains indicates a cohesive international presence. No suspicious domains or partners were identified, reinforcing the company’s reputable standing.

Security posture

The website employs HTTPS with secure cookie attributes such as httpOnly, enhancing visitor security. Cookie consent is managed via Cookiebot, providing granular user control and GDPR compliance. Google Analytics is used with IP anonymization enabled. However, the absence of explicit security headers like Content-Security-Policy or X-Frame-Options is a gap that could be addressed to mitigate certain attack vectors. No security.txt or incident response contact information is published, which limits transparency for vulnerability reporting. No vulnerabilities or exposed sensitive data were detected in the analysis. Overall, the security posture is good but could be improved with additional headers and published security policies.

Recommendations

  1. Implement security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to enhance protection against common web attacks.
  2. Publish a dedicated security policy page and provide incident response contact channels such as security@ or abuse@ emails.
  3. Add a security.txt file at the root domain to facilitate responsible vulnerability disclosure.
  4. Enhance accessibility features to meet higher compliance standards and improve user experience for all visitors.
  5. Regularly audit third-party scripts and dependencies to ensure no vulnerable libraries are in use.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen Sweden AB
Description
Biogen är ett ledande globalt bioteknikföretag som är pionjärer inom vetenskap och driver innovationer inom komplexa och förödande sjukdomsområden. Biogen utvecklar en pipeline med potentiella behandlingar inom neurologi, neuropsykiatri, specialiserad immunologi och sällsynta sjukdomar samtidigt som företaget fokuserar på att bidra med vetenskap som leder till en mer hälsosam, hållbar och jämlik värld.
Content quality
excellent
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent banner with granular controls
  • Use of httpOnly cookies for security

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot session tracker
Marketing tools
Cookiebot
Transparency
good

Site quality

Design
excellent
User experience
good
Content relevance
excellent
Navigation
good
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content in Swedish language.
  2. Strong cookie consent implementation with detailed cookie categories and user controls.
  3. No direct email addresses or phone numbers found on the homepage; contact is via contact page.
  4. Social media presence is well integrated with official Biogen accounts.
  5. No security.txt or explicit security policy page found.
  6. WHOIS data for the domain is unavailable or the domain is not separately registered.
  7. Website uses modern technologies and Adobe Experience Manager CMS.
  8. No signs of malware, phishing, or suspicious behavior detected.
Technical notes

Notes

The website is built on Adobe Experience Manager CMS, utilizing modern JavaScript libraries including jQuery 3.6.4 and Adobe Helix RUM for real user monitoring. Cookiebot manages cookie consent with detailed categorization and user controls. Google Tag Manager and Google Analytics are integrated for analytics and tracking, with privacy features enabled. The site is mobile responsive with good SEO practices including meta tags and Open Graph data. Performance is moderate, with potential improvements in loading speed and accessibility. No hosting provider details were explicitly found. The technical stack reflects a mature enterprise-grade infrastructure suitable for a global biotechnology company.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.se. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.se.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.